COVID 19 Seroprevalence Amongst Healthcare Workers in JHAH
NCT ID: NCT04469647
Last Updated: 2020-07-29
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
1200 participants
OBSERVATIONAL
2020-07-19
2021-06-15
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Serology is an antibody test that provides additional information to polymerase chain-reaction (PCR) testing as it is the only way to reliably establish the fraction of the population that was infected . Seroconversion is the development of antibodies in the blood which can confirm suspected cases after the fact and reveal who was infected but asymptomatic and never realized it. Antibodies are specific proteins created as the body's response to the infection and this test is essential for detecting infected individuals with few or no symptoms at all.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
SARS-CoV-2 (COVID-19) Immune Surveillance Among a Population Based Sample of Adults in Florida
NCT04596579
Natural History of Systemic and Nasal Mucosal Immunity to Influenza and SARS-CoV-2 in Adults After Vaccination
NCT04794829
Dissecting Human Immune Responses to Infection with Influenza or SARS-CoV-2
NCT06848309
Immunologic Responses to Single and Double Doses of COVID-19 Vaccines in Egyptians
NCT04706143
Covid-19 Infection in After Vaccination
NCT05033834
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
CROSS_SECTIONAL
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
High-risk
Employees at high-risk of Coronavirus exposure areas (physicians, nurses, respiratory therapists, radiology technologists, lab technologists, housekeepers)
Serology Test
Participants will be seen at T0 (baseline),T2 (2 months after T0), and T4 (2 months after T2).
at every visit, participants will be asked to complete a general surveillance survey and a blood sample will be taken for the serology test.
Low-risk
Employees working at lower risk areas such as (administration, HR, Public relations)
Serology Test
Participants will be seen at T0 (baseline),T2 (2 months after T0), and T4 (2 months after T2).
at every visit, participants will be asked to complete a general surveillance survey and a blood sample will be taken for the serology test.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Serology Test
Participants will be seen at T0 (baseline),T2 (2 months after T0), and T4 (2 months after T2).
at every visit, participants will be asked to complete a general surveillance survey and a blood sample will be taken for the serology test.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. JHAH employee
3. Housekeepers (this group of staff are outsourced at JHAH)
Exclusion Criteria
18 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Johns Hopkins Aramco Healthcare
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Johns Hopkins Aramco Healthcare
Dhahran, Eastern Province, Saudi Arabia
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Mushcab H, Al-Tawfiq JA, Babgi A, Ghamdi M, Amir A, Sheikh SS, Darwisheh A, AlObaid A, Masuadi E, AlFattani A, Qahtani S, Al Sagheir A. Longevity of Immunoglobulin-G Antibody Response Against Nucleocapsid Protein Against SARS-CoV-2 Among Healthcare Workers. Infect Drug Resist. 2023 May 31;16:3407-3416. doi: 10.2147/IDR.S400365. eCollection 2023.
Mushcab H, Al-Tawfiq JA, Ghamdi M, Babgi A, Amir A, Sheikh SS, Darwisheh A, Alobaid A, Jebakumar AZ, Qahtani S, Al Sagheir A. A Cohort Study of Seroprevalence of Antibodies Against SARS-CoV-2 Infection Among Healthcare Workers at a Tertiary Hospital in Saudi Arabia. Infect Drug Resist. 2022 Aug 10;15:4393-4406. doi: 10.2147/IDR.S369755. eCollection 2022.
Related Links
Access external resources that provide additional context or updates about the study.
Coronavirus disease (COVID-19) technical guidance: The Unity Studies: Early Investigations Protocols
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
IRB20-09
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.